Correlation Analysis of Serum IL-17 and CC-16 Levels with Clinical Prognosis of Patients with Acute Respiratory Distress Syndrome

Abstract

Objective: To investigate the correlation between serum interleukin-17 (IL-17) and Clara cell protein 16 (CC-16) levels and the clinical prognosis in patients with acute respiratory distress syndrome (ARDS). Methods: The data of 120 ARDS patients treated in the First Affiliated Hospital of Hebei North University, in Hebei, China, between Feb. 2020 and Feb. 2022 were retrospectively analyzed. With death as the endpoint event, they were divided into death group (DG) and survival group (SG), based on whether they experienced the endpoint event within 28 days of treatment. All patients underwent serological testing to determine serum IL-17 levels and CC-16 levels, and the scores of Acute Physiology and Chronic Health Evaluation II (APACHE-II) and Sequential Organ Failure Assessment (SOFA) were calculated after enrollment. The IL-17 levels, CC-16 levels, APACHE-II scores and SOFA scores were compared between the two groups. Receiver operator curves (ROC) were adopted used to analyze the predictive value of IL-17 and CC-16 levels for the endpoint event. The correlation of IL-17 and CC-16 levels with clinical prognosis of ARDS patients was evaluated by R analysis. Results: No significant difference was observed in background data between the two groups (p > 0.05). Patients in the DG had significantly higher serum IL-17 and CC-16 levels (p < 0.001), and significantly higher APACHE-II and SOFA scores compared with those in the SG (p < 0.05). The area under the curve of serum IL-17 for predicting 28-day mortality was 0.976 (p < 0.001), while that under the curve of CC-16 was 1.000 (p < 0.001), R analysis demonstrated that serum IL-17 and CC-16 levels significantly correlated with APACHE-II and SOFA scores. Conclusions: Serum IL-17 and CC-16 levels have predictive value for the clinical prognosis of ARDS patients, and higher IL-17 and CC-16 levels indicate a worse prognosis.